Fused Ring Compound Wee-1 Inhibitor Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors, particularly those with impaired G1 checkpoints like P53 deletion, lack effective inhibitors for the Wee1 kinase, which is crucial for regulating the G2-to-M cell cycle transition and is overexpressed in various cancers, hindering targeted therapy.
Innovation Solution
Development of a fused cyclic compound with a specific general formula that acts as a potent inhibitor of the Wee1 kinase, capable of inducing apoptosis in tumor cells by inhibiting the G2 phase checkpoint, thereby selectively targeting and killing tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for tumors are used, then tumor cells can be treated with existing therapies, but there is a lack of effective inhibitors for Wee1 kinase which hinders targeted therapy
Solution Approach 1:
The patent segments the broad category of tumor treatments into specific targeted therapies against Wee1 kinase. By identifying and developing compounds that specifically inhibit Wee1 kinase activity, the invention creates a targeted approach rather than using general tumor treatments, thereby improving therapeutic reliability for tumors with impaired G1 checkpoints.
Solution Approach 2:
The patent introduces fused cyclic compounds as intermediary substances that mediate between the patient's immune system and tumor cells. These compounds specifically bind to and inhibit Wee1 kinase, a key regulatory protein in the cell cycle, thereby preventing tumor cells from repairing DNA damage and selectively inducing apoptosis in cancer cells while sparing normal cells.
2Object-affected harmful factors
If Wee1 kinase activity is inhibited, then tumor cells undergo apoptosis due to inability to repair DNA damage, but normal cells may also be affected
Solution Approach 1:
The patent applies local quality by exploiting the differential expression and function of Wee1 kinase in tumor versus normal cells. Tumor cells with impaired G1 checkpoints (such as p53 deletion) rely heavily on the G2 checkpoint for DNA damage response, making them locally vulnerable to Wee1 inhibition. Normal cells with intact G1 checkpoints can still survive because they have alternative protective mechanisms, thus achieving selective toxicity against tumor cells.
Solution Approach 2:
The patent employs preliminary anti-action by pre-inhibiting Wee1 kinase activity before DNA damage occurs or at the onset of cell cycle progression. This prevents tumor cells from activating the G2 checkpoint mechanism that would normally allow them to repair DNA damage and survive. By blocking this protective pathway in advance, the therapy selectively eliminates tumor cells that would otherwise be resistant to conventional treatments.
3Reliability
If a specific fused cyclic compound structure is developed, then potent Wee1 kinase inhibition is achieved, but the complexity of compound synthesis increases
Solution Approach 1:
The patent segments the complex fused cyclic compound structure into multiple synthesizable components or building blocks. By dividing the molecular structure into manageable fragments that can be synthesized separately and then assembled, the invention reduces the overall synthesis complexity while maintaining the potent inhibitory activity against Wee1 kinase that the complete fused cyclic structure provides.
Data Source
AI summary
The present invention discloses a fused cyclic compound as a Wee-1 inhibitor. Specifically, the present invention relates to a compound of general formula (1), a method for preparing same, and use of the compound of general formula (1) or an isomer, a crystalline form, a pharmaceutically acceptable salt, a hydrate or a solvate thereof as a Wee-1 inhibitor in the preparation of an anti-tumor drug.